DiscGenics to Present at 40th Annual J.P. Morgan Healthcare Conference
PR93959
SALT LAKE CITY, Jan. 6, 2022 /PRNewswire=KYODO JBN/ --
DiscGenics (https://c212.net/c/link/?t=0&l=en&o=3404974-1&h=3114304150&u=https%3A%2F%2Fwww.discgenics.com%2F&a=DiscGenics), Inc.,
a privately held, clinical stage biopharmaceutical company focused on
developing regenerative cell-based therapies that alleviate pain and restore
function in patients with degenerative diseases of the spine, today announced
that Chief Executive Officer and Chairman Flagg Flanagan will present at the
40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at
9:00 a.m. EST.
Logo - https://mma.prnewswire.com/media/561675/DiscGenics_Logo.jpg
Invited attendees of the Conference can access the virtual session for both
live and on demand replay.
About DiscGenics
DiscGenics is a privately held, clinical stage biopharmaceutical company
focused on developing regenerative cell-based therapies that alleviate pain and
restore function in patients with degenerative diseases of the spine. As the
only company in the world to develop an allogeneic cell therapy derived from
intervertebral disc cells to treat diseases of the disc, DiscGenics believes it
has a unique opportunity to harness the restorative potential of the human body
to heal millions of patients suffering from the debilitating effects of back
pain. DiscGenics' first product candidate, IDCT, is a homologous, allogeneic,
injectable cell therapy that utilizes biomedically engineered progenitor cells
derived from intervertebral disc tissue, known as Discogenic Cells, to offer a
non-surgical, potentially regenerative solution for the treatment of patients
with mild to moderate degenerative disc disease. For more information, visit
www.discgenics.com.
SOURCE: DiscGenics, Inc.
CONTACT: Lindsey Saxon, lindsey@discgenics.com; Colin Novick (Japan),
colin.lee.novick@cj-partners.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。